CRBP · Corbus Pharmaceuticals Holdings, Inc.

0001193125-26-219707

Summary

Clinical-stage losses widened in Q1 2026 versus prior year as operating expenses increased on clinical program investments, with cash burn accelerating amid ongoing pipeline advancement and no revenue generation.

Key takeaways

Operating income was -$24.3M, worsening 22.9% year-over-year due to higher operating expenses from clinical investments.
Diluted EPS was $-1.23, improving 11.5% year-over-year despite larger net loss, reflecting share dynamics.
Free cash flow was -$25.6M, reflecting net cash used in operating activities of -$25.6M net of minimal capex.

Full analysis

These dynamics highlight Corbus's capital requirements and reliance on external funding, where failure to raise capital as needed could impair its business strategy. With ongoing trials and no revenue visibility until regulatory approvals years away, the quarter exemplifies the financial profile of a development-stage biotech navigating pipeline risks and liquidity needs.